Decibel Cannabis Faces a $2.09 Share Offer as Investors Eye International Growth

Worthy Endeavor — Weekly Feature | November 6, 2026

Decibel Cannabis is attracting investor attention after Ewing Morris raised its partial tender offer to C$2.09 per share. With international sales expanding and a November 13 deadline approaching, shareholders face a new decision.

A Canadian cannabis producer is facing an unusual moment in the market, and investors have just one week to decide what comes next.

Decibel Cannabis Company (TSX-V: DB), a Calgary-based producer of branded cannabis products, is at the center of a revised cash offer from investment firm Ewing Morris. On November 4, the firm increased its unsolicited partial tender offer from C$1.91 to C$2.09 per share, describing the new price as its best and final proposal.

The offer covers up to 2,392,345 existing shares, representing approximately 6% of the company, and is scheduled to expire on November 13.

Importantly, this is not a takeover. Ewing Morris is offering to purchase shares directly from existing shareholders rather than acquire the entire business. Decibel will remain independent, and no new shares will be issued as part of the transaction.

If more shares are tendered than the offer permits, purchases will be allocated proportionately, meaning participating investors may not be able to sell their entire holdings.

For a company valued at approximately C$75 million in early November, the proposed transaction is significant. If fully subscribed, the offer would involve approximately C$5 million in cash.

But the tender is only part of the investment story.

Decibel operates an established cannabis business with a growing international presence. Its portfolio includes Qwest, General Admission, and Standard Issue, covering products such as dried flower, infused pre-rolls, and vape products.

The company operates facilities in Alberta, Saskatchewan, and Ontario, including an EU-GMP-licensed cultivation and processing facility in Chatham. That certification supports its ambitions to expand into regulated international medical cannabis markets.

International growth has become an increasingly important opportunity as Canadian producers continue facing competitive pricing pressures at home.

Decibel's trailing twelve-month revenue stood near C$127 million, while recent quarterly revenue growth reached the high teens. Management has also raised its full-year revenue guidance to approximately C$132 million to C$137 million.

These figures suggest that the company is building commercial momentum beyond its established Canadian operations.

However, international expansion comes with challenges. Regulatory requirements differ between markets, and growing export volumes can increase working-capital demands before revenue converts into cash.

The company's balance sheet also deserves attention.

Decibel reported approximately C$10 million in cash against roughly C$58 million in total debt, leaving net debt near C$48 million. Although its current ratio of approximately 2.4 indicates that current assets exceed current liabilities, maintaining consistent cash generation remains important.

A credit facility with ATB Financial provides additional financial flexibility, but the company must continue balancing investment in growth with debt management.

Competition presents another challenge. Larger cannabis producers, including Canopy Growth, Aurora Cannabis, and Organigram, are also pursuing opportunities in domestic and international markets.

Decibel has sought to differentiate itself through branded products, particularly infused pre-rolls, alongside its expanding export capabilities.

For shareholders, the Ewing Morris tender introduces a separate question from the company's long-term operating outlook.

The C$2.09 offer provides an opportunity for some investors to sell shares for cash at a stated price, but it does not establish the value of the entire company. Investors who choose not to participate remain exposed to Decibel's future performance and market movements.

The company's board and management have indicated they do not intend to tender their holdings.

With the November 13 deadline approaching and another earnings report expected around mid-November, Decibel faces two important near-term events: the outcome of the partial tender and another opportunity to demonstrate whether international growth is translating into stronger financial performance.

Investor Take

Decibel Cannabis presents an interesting combination of an established operating business, expanding international revenue, and an unusual shareholder liquidity event.

The revised C$2.09 tender offer creates a near-term catalyst, but investors should distinguish between the price offered for a limited number of shares and the company's longer-term market valuation.

The bigger investment question is whether Decibel can turn international expansion into sustainable free cash flow while managing approximately C$58 million in debt.

For now, the November 13 tender deadline and upcoming earnings will be the developments to watch.

What We're Watching

The immediate focus is the level of shareholder participation in the Ewing Morris tender offer and whether demand exceeds the number of shares available for purchase.

Beyond that, investors will be watching international export growth, profitability, debt management, and the company's ability to deliver on its increased revenue guidance.

This is editorial research for Worthy Endeavor, not an investment recommendation.